• New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas
• Investment reinforces the importance of the Rhineland-Palatinate site within AbbVie’s global network
• Construction of the new R&D building expected to complete in 2027

LUDWIGSHAFEN, Germany, April 29, 2024 – AbbVie breaks ground on a new central research building, “LUnA” (LUdwighafens neue Arbeitswelt) and is investing approximately €150 million in its second largest R&D location worldwide. A state-of-the-art research and laboratory building is being built on the main campus and will be home to more than 300 researchers and scientists. The facility will be built with modern and sustainable infrastructure features, creating flexible working conditions that enable greater scientific exchange between different areas of research and implement automation and digital research capabilities.

With this investment, AbbVie reinforces that the Rhineland-Palatinate site, with its more than 2,000 employees, will continue to be a critical component of AbbVie’s global network. All employees make a significant contribution to successfully advancing AbbVie's pipeline with the goal of developing new therapies for serious diseases across oncology, neuroscience and immunology that can potentially improve the lives of millions of patients.

“For AbbVie Germany, the new construction of our 'LUnA' research building is much more than a €150 million investment in cutting-edge infrastructure. It is a promise for the future of AbbVi…